STROME MARK E

10% owner STROME MARK E buys 100.0K ZIVO shares at $2.00; stock down -93.7% from 52-week high, down -85.4% in 30 days.

STROME MARK E, a 10% owner, purchased 100,000 shares at $2.00 on 2026-04-17, increasing holdings by 21.1% to 572,942 shares. The timing is concerning: the stock trades at $1.20, down -93.7% from its 52-week high of $19.01 and down -85.4% over the past 30 days. His track record at this same ticker shows poor outcomes—three prior buys at ZIVO resulted in average 90-day returns of -15.1% (2024-12-26 buy down -15.3%, 2025-10-13 buy down -24.6%), with 0 of 2 prior buys well-timed at the 90-day mark. This latest purchase into a steep and accelerating decline, following a pattern of unsuccessful accumulation at ZIVO, suggests the insider's recent capital deployment has not been rewarded. The company remains unprofitable with net income of $-1.0M, adding fundamental risk to the price deterioration.

Director Strome buys 750.0K shares of BEAT at $0.80; stock down 76.4% from 52-week high; 7 other insiders bought in 14 days

Director Mark E. Strome purchased 750,000 shares at $0.80 on 2026-04-16, increasing his holdings by 25.9% to 3.65M shares. The purchase occurs in a cluster context: 7 other insiders also bought within the past 14 days. However, this coordinated activity and the stock's deteriorating fundamentals—HeartBeam reported a net loss of $-5.3M on a $33.3M market cap—warrant scrutiny against Strome's own cross-ticker track record, which shows 3 prior buys with an average 90-day return of -20.0% and a 0.00% win rate. The stock is currently trading at $0.81, down 76.4% from its 52-week high of $3.44 and down 37.7% over the past 30 days, creating an apparent disconnect between the concentrated buying activity and the stock's steepening price deterioration.

10% Owner Strome buys 20,000 ZIVO shares at $9.77; stock at -53.5% from 52-week high, prior buys at this ticker showed 90d losses.

Mark E. Strome, a 10% shareholder, purchased 20,000 shares at $9.77, increasing his holdings from 452.9K to 472.9K shares. The transaction occurred at a significant discount to the 52-week high of $21.49, but Strome's own track record at this ticker shows two prior buys (2025-10-13 and 2024-12-26) that each declined over 90 days (-3.6% and -24.6% respectively), with a 0% success rate at the 90-day mark. The company remains unprofitable with a net loss of $1.0M in the most recent period, offsetting strong revenue growth of 468.6% year-over-year. While the recent 30-day price appreciation of +11.1% may have prompted the purchase, the lack of prior successful timing by this insider at ZIVO and the company's continued losses present a cautious context for this accumulation.

10% owner Mark Strome bought 20,259 shares of ZIVO at $12.34; cluster buy by 2 other insiders in 14 days

Mark Strome, a 10% shareholder, purchased 20,259 shares at $12.34 on 2025-10-13 for $249,996.06, increasing his holdings to 452,942 shares (+4.7%). This buy occurred as part of a cluster pattern, with 2 other insiders also purchasing within the past 14 days. However, context dampens the signal: Strome's prior buy at ZIVO (2024-12-26) resulted in -15.3% return over 90 days, and his cross-ticker track record shows 0 of 1 prior buys well-timed at the 90-day mark. The company's fundamentals are weak—it posted $-1,640,232.00 net income on $53,400.00 quarterly revenue and remains unprofitable, though annual revenue growth reached +468.6%. The stock is down -38.9% from its 52-week high, trading at $13.50 versus the $12.34 transaction price. The multi-insider buying gesture and recent revenue growth stand against a pattern of insider losses and persistent unprofitability.

10% Owner Strome Buys 75,000 ZIVO Shares at $20.19, Raising Stake to 398.7K Shares Amid Unprofitability

Strome, a 10% beneficial owner of Zivo Bioscience, acquired 75,000 shares for $1,514,250.00 on 2024-12-26, increasing his shareholding by 23.2% to 398.7K shares. The purchase occurred at $20.19, within 6.1% of the current market price of $21.50 and near the 52-week high of $22.10. However, this accumulation takes place against a backdrop of severe operational distress: the company generated only $31,500.00 in quarterly revenue and posted a net loss of $-2,268,597.00, with unprofitability extending across its most recent full fiscal year. The stock has gained 30.8% over 90 days and 4.9% over 30 days, placing the purchase near recent peaks despite the company's inability to achieve profitability at scale. This pattern—a substantial increase in ownership stake by a 10% holder during a period of significant operating losses—warrants investor scrutiny into the rationale behind the accumulation and the company's path to sustainability.